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Abuse of amphetamine-type stimulants (ATS) has become a global public health
problem. ATS causes severe neurotoxicity, which could lead to addiction and could
induce psychotic disorders or cognitive dysfunctions. However, until now, there has been
a lack of effective medicines for treating ATS-related problems. Findings from recent
studies indicate that in addition to the traditional dopamine-ergic system, the GABA
(gamma-aminobutyric acid)-ergic system plays an important role in ATS abuse. However,
the exact mechanisms of the GABA-ergic system in amphetamine-type stimulant use
disorders are not fully understood. This review discusses the role of the GABA-ergic
system in ATS use disorders, including ATS induced psychotic disorders and cognitive
dysfunctions. We conclude that the GABA-ergic system are importantly involved in the
development of ATS use disorders through multiple pathways, and that therapies or
medicines that target specific members of the GABA-ergic systemmay be novel effective
interventions for the treatment of ATS use disorders.
Keywords: GABA system, amphetamine-type stimulants use disorders, psychotic, cognitive dysfunctions, drug
abuse
Introduction
Abuse of amphetamine-type stimulants (ATS), including amphetamine, methamphetamine
(METH), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyamphetamine
(MDA), is a global public health problem. According to the United Nations World Drug Report,
approximately 0.3–1.3% of the world’s population suffers from ATS abuse problems (Burns, 2014).
The use of ATS causes serious social problems, including violence (Pluddemann et al., 2010),
criminal behavior (Cartier et al., 2006), and an increased prevalence of AIDs (Halkitis et al., 2001;
Colfax and Guzman, 2006).
ATS comprise a class of psychoactive substances, and long-term use of ATS results in addiction
(Cretzmeyer et al., 2003; Cruickshank and Dyer, 2009). However, large dose or long-term use of
ATS may also result in psychiatric disorders or cognitive deficits (Batki and Harris, 2004; Curran
et al., 2004). Psychotic symptoms include hallucinations and delusions (Bramness et al., 2012),
which are similar to the clinical features of schizophrenia. According to the reports, the prevalence
of psychosis in methamphetamine abusers ranges between 10 and 60% (Farrell et al., 2002; McKetin
et al., 2006; Mahoney et al., 2008). Various animal behaviors, such as increased activation and
hallucinogenesis in non-human primates (Castner and Goldman-Rakic, 1999), and increased
locomotion activity, stereotyped behavior, deficits in prepulse inhibition and latent inhibition, or
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behavior sensitization in rodents (Robinson and Becker, 1986;
Tenn et al., 2003; Featherstone et al., 2007; Chen et al., 2010;
Macedo et al., 2012), resemble human psychiatric disorders. The
clinical manifestations of ATS-induced cognitive dysfunction
include (Scott et al., 2007; Jacobs et al., 2008) response inhibition
and deficits in learning, memory, attention, and decision
making, social cognition, executive functions, and working
memory. Research in animal models demonstrates that ATS
could cause impairment to cognitive functioning in animals
(Belcher et al., 2005; Camarasa et al., 2010; Herring et al.,
2010).
The major mechanism of ATS addiction is traditionally
though to be increased activity of the mesolimbic dopamine
system. However, until now, there has been a lack of effective
medicines for treating ATS-related problems. Indeed, emerging
evidence that will be discussed in this paper suggests that a
GABA-ergic dysfunction may also result in ATS use disorders,
including ATS-induced psychiatric disorders and cognitive
dysfunction. We hope this review will help to elucidate the
mechanisms underlying ATS use disorders as well as aid in the
development of novel interventions.
This review focuses on the role of the GABA-ergic system
in ATS use disorders. In the following manuscript, we first
discuss the impacts of ATS on the GABA system, including
GABA receptors, transporters, and so on. We further discuss
addiction-related brain regions in ATS use disorders, such the
prefrontal cortex, striatum, and the involvement of GABA
system in the dysfunctions of these neural circuits. In addition,
we also document the genetic evidence on the relationship
between GABA system and ATS use disorders, and review
some clinical applications of GABA system medicines to
treat ATS use disorders. Thus, this review summarizes the
involvement of GABA-ergic system in ATS use disorders,
providing us with a new aspect on research on ATS use
disorders.
ATS Change the Functions of the GABA
System
GABA, which is the main inhibitory neurotransmitter in
the central nervous system (CNS), works with excitatory
neurotransmitters to maintain the normal functions of the
CNS. The GABA system, including GABA receptors, GABA
transporters (GAT), and glutamate decarboxylase (GAD), is
widely distributed in the CNS and is related to ATS use disorders.
GABA Receptors and ATS Use Disorder
GABA receptors include ionotropic receptors (GABAA and
GABAC) and metabotropic receptors (GABAB). The ionotropic
GABA receptors are ligand-gated ion channels, which mediate
fast inhibitory synaptic transmission in neurons, whereas the
metabotropic GABAB receptors belong to the superfamily of
G-protein coupled receptors (GPCRs) which are responsible
for the neuromodulation of GABA (Benarroch, 2012). Of these
GABA receptors, GABAA, and GABAB are the most well-studied
receptors in ATS use disorders.
ATS Influence the Normal Functions of GABAA
Receptors
The ionotropic GABAA receptors are the major inhibitory
neurotransmitter receptors that mediate fast synaptic
transmission inhibitory effects. GABAA receptors are composed
of five protein subunits that belong to different subunit classes,
including subunits α1-6, β1-3, γ1-3, δ, ε, θ1-3, pi, and ρ1-3
(Simon et al., 2004). The GABAA α1β2γ2 receptor subtype
combination is the most abundant subtype in most brain
areas (McKernan and Whiting, 1996). Importantly, GABAergic
signaling in dopaminergic brain areas, like the Ventral Tegmental
Area (VTA) and the substantia nigra compacta, is also mainly
mediated by the GABAA α1β2γ2 receptor subtypes (Petri et al.,
2002).
Recent research has shown that the use of ATS would
influence the normal functions of GABAA receptors. One study
(Hondebrink et al., 2013) using a two-electrode voltage-clamp
technique showed that administration of ATS in Xenopus
oocytes expressing human GABAA α1β2γ2 receptor subunits
directly inhibited a GABAA receptor-evoked electric current,
possibly via competitive binding to one of the GABA binding
sites, which represented decreased potential intensity. A similar
study (Hondebrink et al., 2011) displayed an inhibitory effect
by ATS on GABAA receptor-induced inhibitory potential
in the nervous system. If present in vivo, this decreased
inhibitory GABA-ergic input on, for example, dopaminergic
neurons, may resulted in enhanced drug-induced DA release
and drug addiction. In support of this finding, animal
studies have demonstrated that pretreatment with clonazepam
(a GABAA receptor agonist) prevented the acquisition of
behavioral sensitization of methamphetamine in rats (Ito
et al., 2000). Alternatively, antagonism of GABAAreceptors
aggravates ATS-induced disorders. Intra- prefrontal cortex (PFC)
injection of a GABAA receptor antagonist, dicentrine, enhanced
amphetamine-induced psychomotor activation (Enomoto et al.,
2011). The mechanism could be that the activation of GABAA
receptor decreases dopaminergic neurotransmission, which
could be increased by inhibition of GABAA receptor, suggesting
that GABAAreceptors may play an inhibitory role in ATS use
disorders.
ATS Influence the Normal Functions of GABAB
Receptors
The GABAB receptors are G-protein-coupled receptors
with seven transmembrane domains. The two subunits of
a GABABreceptor are GABAB1 and GABAB2. The GABAB
receptors are located on the pre- and post-synaptic sites.
Activation of the presynaptic GABAB receptors inhibits
calcium ion flux from extracellular to intracellular sites by
blocking calcium channels and thus inhibits transmitter release.
Activation of the post-synaptic GABAB receptors, however,
activates the potassium channels and increases the intracellular
potassium concentration, leading to neuron hyperpolarization
and producing a slow inhibitory post-synaptic current (IPSC).
Recent research has shown that the use of ATS depressed
the normal functions of the GABAB receptors-GIRK
(G-protein-gated inwardly rectifying potassium, GIRK/Kir3)
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channels. Padgett et al. (2012) showed that a single in vivo
injection of METH depressed GABAB receptors-GIRK channels
in VTA GABA neurons. Thus, it enhanced VTA GABA
neuron firing, which may augment GABA transmission in
VTA. The VTA GABA neurons provide a local source of
GABA for controlling the firing of VTA DA neurons. These
neuro- adaptations in the GABA neurons are predicted to
increase the GABA-mediated inhibition of VTA DA neurons.
However, repeated psychostimulant administration leads to
increased firing rates of VTA DA neurons and development
of ATS addiction. Thus, the increase of GABA-mediated
inhibition of VTA DA neurons, which is efficient at first,
may suggest that short-term use of ATS would enhance the
compensatory enhancement of GABA, whereas large doses
and long-term use would eventually lead to depression in the
GABAB receptor signaling in DA neurons. Few research has
examined the effects of methamphetamine on GABAB receptors
in DA neurons; however, the following evidences indicate that
methamphetamine causes impairment to the GABAB receptors
in DA neurons.
Some studies have suggested that GABAB receptor agonists
may be useful for decreasing amphetamine-induced dopamine
release and treating ATS use disorders. One study (Balla et al.,
2009) showed that injection of GABAB receptor agonists,
SKF97541 or baclofen, into the PFC significantly reduced the
basal dopamine level and decreased amphetamine-induced
dopamine release in rats. The GABAB receptor agonist
baclofen could block the development of ATS- induced
behavior sensitization (Bartoletti et al., 2005) and attenuate
ATS self-administration in rats (Brebner et al., 2005). Baclofen
and GABAB positive allosteric modulators, GS39783 and
CGP7930, which specifically activate the GABAB receptors,
inhibited the expression of methamphetamine-induced
conditioned place preference (Halbout et al., 2011; Voigt
et al., 2011). These findings indicate that the action of GABAB
receptor agonists may be a target for the treatment of ATS use
disorders.
Impact of ATS on Other GABA System Members
(GAT, GAD, and Glutamate)
The GABA transporter (GAT), another important member of
the GABA system, is located at the synapses of the GABA-ergic
neurons; GAT is responsible for GABA reuptake and thus
maintains the basal GABA level in the extracellular space. GAT is
also important for the regulation of synaptic transmissions of the
GABA-ergic neurons. Four distinct transporters for the GABA
are GAT-1, GAT-2, GAT-3, and BGT-1(Borden et al., 1995).
Animal experiments have shown that when mice were treated
with ATS, the immune activity of striatal GAT-1, a predominant
GABA transporter, was enhanced, suggesting the possibility of an
increased reuptake of GABA, which may be the main explanation
for the decreasedGABA level in the extracellular space (Izco et al.,
2010).
GAD is a specific GABA synthetase and is positively correlated
with the GABA levels in various brain regions. Two isoenzymes
determined by different molecular weights are GAD65 and
GAD67. In a rat behavioral sensitization mode (Zhang et al.,
2006), methamphetamine was reported to decrease the GAD67
protein level in the NAc, suggesting an inhibitory effect on the
GABA-ergic neurotransmitter caused by ATS. This inhibition
is related to ATS-induced locomotor sensitization. This study
also found that the GAD67 protein level increased in the
striatum, which is consistent with the findings of another
study (Pereira et al., 2008), which showed that amphetamine
induced an elevation of the GABA levels in the striatum. Some
opposing phenomena show that methamphetamine significantly
decreased GAD67 mRNA and protein levels or the GABA
level in the striatum (Jayanthi et al., 2004; Pereira et al.,
2012). One possible explanation is that short-term or low-
dose methamphetamine use (30mg/kg, for 1 day) (Pereira
et al., 2008) induced compensatory enhancement of the striatal
GABA level, whereas long-term or high-dose methamphetamine
use (40mg/kg, for 7 days) (Jayanthi et al., 2004) induced
apoptosis of the GABA-ergic neurons and decreased the level
of GAD in the striatum of rats. The second explanation is
the following difference in animal species; mice appear to be
more susceptible to ATS than rats. The identical dosage of
ATS (30mg/kg) induced a compensatory enhancement of the
GABA level in the striatum of rats (Pereira et al., 2008) and
decreased the GABA level in C57BL/6 adult mice (Pereira et al.,
2012).
GABA is derived from glutamate under the decarboxylation
action of GAD, via glutamine-glutamate-GABA circulation;
thus, changes in the glutamate level could affect the GABA
content as well. Studies have found that ATS use could change
the glutamate levels in the brain. Animal experiments have
demonstrated that a single dose of ATS (30mg/kg) in mice led
to decreased levels of glutamine, glutamate, and GABA in the
corpus striatum and down-regulated the glutamine/glutamate
and GABA/glutamate ratios, suggesting a circulatory disturbance
of the glutamine-glutamate-GABA circuit (Pereira et al., 2012).
Bu et al. (2013) treated rats with 2.5mg/kg of ATS twice a
day for over 7 days and detected reduced GABA, glutamate,
and glutamine levels in the PFC. Using magnetic resonance
spectroscopy (MRS) in ATS addicts, Sailasuta et al. (2010) found
abnormal glutamine-glutamate circulation in neuroglia cells. The
reduction of the glutamate level was hypothesized to be due to
over-excitation of the glutamate system induced by ATS, and
an excessive need for glutamate was produced. The decreased
GABA level was caused by an insufficiency of glutamate, the
synthetic ingredient of GABA. Additionally, ATS could promote
GABA metabolism into succinic acid semialdehyde, for which
an increased level was found after the ATS treatment (Bu et al.,
2013).
The existing evidence showed that ATS can change the
functions of multiple members of the GABA-ergic system.
Although short-term use of ATS may enhance the compensatory
enhancement of GABA, large doses and long-term use
will lead to insufficient GABA synthesis and increased
decomposition, thus decreasing GAD and GABA levels.
ATS can reduce GABAA and GABABreceptor functioning
and increase the function of GAT. These changes by ATS
eventually lead to a decrease in GABA-ergic system function (see
Figure 1).
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FIGURE 1 | Large doses and long-term use of ATS lead to an decrease
on GABA-ergic system function. The up and down arrows represent the
decreased or increased level or function and the X marks represent the
decreased function. GABA, gamma-aminobutyric acid; GAD, glutamic acid
decarboxylase; GAT, GABA transporters; GABAA, GABAA receptor; GABAB,
GABAB receptor. (1) GABAA receptor: ATS directly inhibit a GABAA
receptor-evoked electric current, possibly via competitive binding to one of the
GABA binding sites. (2) GABAB receptor: ATS depress the normal functions of
the GABAB receptors-GIRK channels. (3) GAD: ATS decrease the GAD67
protein level in the NAc, suggesting an inhibitory effect on the biosynthesis of
GABA-ergic neurotransmitter caused by ATS. (4) GAT: ATS increase the
expression of striatal GAT-1, which could be a possible explanation for the
reduction of extracellular GABA expression. (5) ATS could promote GABA
metabolism into succinic acid semialdehyde.
ATS Abuse Impairs Normal Functions of
GABA System in Related Regions
Abnormal activation of the dopamine systems in the
nigrostriatal, mesolimbic, or mesocortical pathways have
been regarded as the three classic pathways involved in drug
addiction. Because the GABA system plays an important role in
ATS addiction as well, the following section focuses on changes
in the GABA system in these three classic pathways, including
the ventral tegmental area (VTA), prefrontal cortex, and striatum
in ATS use disorders.
ATS Disrupt the Inhibitory Function of GABA
System in VTA
In the last decade, a large number of studies, at the cellular and
animal behavioral levels, have shown that, under the stimulation
effect of addictive drugs, projections from the VTA dopamine
neurons, particularly the enhanced dopamine projection from
VTA to NAc, are the main neural mechanisms underlying
substance dependence (Luscher and Ungless, 2006; Schultz,
2006).
Additionally, ATS abuse is correlated with changes in
the VTA-NAc pathway. Acute application of ATS increases
dopamine release from the VTA to the NAc through the
mesolimbic and mesocortical pathways (Kankaanpaa et al., 1998;
Zhang et al., 2001). Over-activation of the NAc dopamine
neurons produces euphoria and connects this emotion with
conditional signals, thus constituting the neural basis of the
induction of drug craving and drug-seeking behaviors (Haber
and Knutson, 2010). Repeated or long-term use of ATS causes
sustained adaptive changes in the mesolimbic circuit neurons,
namely neural plasticity, which ultimately leads to a stable drug
addictive state (Koob and Le Moal, 2001; Luscher and Malenka,
2011).
More than 30% of the neurons in the VTA are GABA-ergic
neurons (Creed et al., 2014). There are two types of GABA-ergic
neurons, as follows: GABA-ergic interneurons, which produce an
inhibitory effect on local VTA dopamine neurons; and GABA-
ergic projection neurons, which depress their projected brain
regions. Some reports (Tan et al., 2012; van Zessen et al.,
2012; Bocklisch et al., 2013) have demonstrated that when
GABA-ergic neurons in the VTA are activated, the activation of
dopaminergic neurons, locally and in its projected regions, are
strongly inhibited. Alternatively, inhibition of the VTA GABA-
ergic neurons causes an enhanced activation of dopaminergic
neurons locally and in its projected regions. Many studies have
shown that the GABA system plays an important role in the
ATS-induced over-activation of the NAc dopamine neurons. One
study (Giorgetti et al., 2002) showed that after 5 days of injection
with 5mg/kg ATS and 3 days of withdrawal, microinjection of
the GABAB receptor antagonist into the VTA in rats caused
significant increases in the glutamate and dopamine levels
compared with those in the non-ATS treated control group. The
results indicated that under the effect of ATS, the brain would
mobilize the GABA inhibitory effect in the VTA to maintain
normal dopamine and glutamate levels in a self-protective
manner. This imbalanced inhibitory effect might be a possible
explanation for ATS use disorder, and this result was supported
by another study (Bankson and Yamamoto, 2004; Padgett et al.,
2012). All of these studies showed that protecting or enhancing
the GABA inhibitory effect on dopamine and glutamate neurons
in the VTA might provide a strategy for treating ATS addiction.
ATS Disturb the Inhibitory Function of the GABA
System in PFC
The prefrontal cortex is unique to the evolution of primates.
The human prefrontal cortex is involved in many complicated
cognitive processes, such as logical thinking, working memory,
decision making, and organization of behavior (Fuster, 2000;
Brown and Bowman, 2002; Kasanetz et al., 2013). As part of the
mesolimbic circuit, the PFC plays a very important role in drug
abuse and addiction (Roberts et al., 1998; Daglish et al., 2003).
Injury to the PFC could cause impairment of judgment, planning,
and the capacity for decision making, the so-called “executive
dysfunction syndrome” (Roberts et al., 1998). Recent research
(Baler and Volkow, 2006; Kasanetz et al., 2013) hypothesized that
an important explanation for addiction is impairment to the PFC,
which results in executive dysfunction and leads to uncontrolled
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drug-taking behavior. As a result, the PFC dysfunction by ATS is
responsible for ATS-induced psychosis and cognitive dysfunction
and is closely related to ATS addiction.
In the primate neocortex, the GABAergic neurons constitute
approximately 25–30% of the neuronal population (Jones, 1993).
They are interneurons, and they maintain the normal functions
of the PFC pyramidal cells though their inhibitory effects on the
dopaminergic neurotransmitter (projecting from the VTA) and
glutamatergic neurotransmitters (projecting from the thalamus)
(Jones, 1993; Gabernet et al., 2005).
Acute use of ATS increases the glutamate level in the PFC
(Stephans and Yamamoto, 1994; Qi et al., 2009), and moderate
activation of the glutamatergic neurons plays an important role
in synaptic plasticity, which is closely related to cognitive learning
(Luo et al., 2002; Abraham and Williams, 2003). Over-activation
or long-term activation of the glutamatergic neurons by ATS
could produce excitatory neurotoxicity and cause cell apoptosis.
Apoptosis of the PFC pyramidal cells induces functional
disorders of the PFC, and, finally, results in addiction, psychosis,
and cognitive dysfunction (Deng et al., 2001; Kuczenski et al.,
2007). Apoptosis of the PFC GABA interneurons reduces their
inhibitory effects on the dopaminergic neurotransmitters and
glutamatergic neurotransmitters (see Figure 2).
Additionally, acute use of ATS facilitates the projection of
dopamine from the VTA to the PFC though the mesolimbic
pathway (Haber and Knutson, 2010). The stimulation of the D1-
like dopamine receptors located on the glutamatergic terminals
induced enhancement of the glutamate release (Licata and
Pierce, 2003), so dopamine further increased the excitatory
neurotoxicity of glutamate. Repeated amphetamine treatment
leads to potentiated interactions between DA and glutamate
transmission (Giorgetti et al., 2001).
The PFC GABA-ergic interneurons suppress over-activation
of the dopaminergic and glutamatergic neurons, and ATS
might exacerbate these effects by disturbing the inhibitory
function of the GABA-ergic neurons. As reported by
Brummelte’s group (Brummelte et al., 2007), early treatments
with methamphetamine triggered changes in the post-natal
maturation of the prefrontal cortical GABA-ergic neurons in
Mongolian gerbils and led to a decreased inhibitory regulatory
effect by the GABA-ergic interneurons. In another experiment
(Enomoto et al., 2011), researchers used a GABAA receptor
antagonist, bicuculline, to block the GABAA receptors in the
PFC of rats and found a significant increase of ATS-induced
locomotion in adult rats. This finding may be due to the
uncontrolled over-activation of dopaminergic and glutamatergic
neurons, which causes impairment to the PFC function and is
closely related to addictive memories.
Microinjections of the GABAB receptor agonists, baclofen, or
SKF-97541, into the PFC of rats, significantly reduced the local
extracellular dopamine basal level, as well as the ATS-induced
dopamine release (Balla et al., 2009). Baclofen improved ATS-
induced cognitive dysfunction, suggesting a relationship between
the GABA system and PFC function (Arai et al., 2009). It could
be hypothesized that improving the function of the GABA system
would have a protective effect in ATS-induced PFC nerve injury,
although there is no direct evidence from human studies.
ATS Abuse Disrupts Functions of the Striatum
and Its Related Neural Circuit via GABA System
ATS Abuse Impairs Strital Structure and Functions
Accumulating data have confirmed that the striatum plays an
important role in ATS use disorder. An MRI study (Chang et al.,
2005) on ATS-dependent patients demonstrated that long-term
use of amphetamine led to enlargements of the caudate nucleus,
pallidum, and putamen of the basal nuclei; this enlargement
maybe a local inflammatory reaction caused by amphetamines.
Other sub-cortex regions, such as the thalamus, midbrain,
cerebellum, and callosum, were unaffected. In people with a large
accumulation of amphetamines or mental symptoms induced
FIGURE 2 | ATS disturb the inhibitory function of GABA
interneurons in PFC and impairs the function of PFC pyramidal
cells. Left panel: Normal state in the PFC. Right panel: ATS increase
the glutamate and dopamine levels in the PFC, and exacerbate these
effects by disturbing the inhibitory function of the GABA-ergic
interneurons. Over-activation or long-term activation of the glutamatergic
and dopaminergic neurons by ATS could produce excitatory
neurotoxicity and cause pyramidal cell apoptosis.
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by ATS, the striatum becomes even smaller. This phenomenon
suggests that long-term use of amphetamines may ultimately
result in apoptosis of striatal cells and reduced striatum volume.
In fetuses with long term prenatal methamphetamine exposure,
the putamens, and pallidums were smaller than those in
methamphetamine-free fetuses (Chang et al., 2004), suggesting
the influence of ATS on the growth and development of
children. Animal studies demonstrated that a large dose of
methamphetamine induced neuronal apoptosis of the striatum
neurons, which could be an important explanation for the
shrinkage of the striatum (Jayanthi et al., 2004; Zhu et al., 2006).
Relationship between GABA System and the Striatal
Related Neural Circuit (see Figure 3: Top Panel)
Approximately 77% of the striatal neurons are GABA-ergic
projection neurons (Graveland et al., 1985) that project to
different brain regions. One type of GABA-ergic neuron projects
to the substantia nigra pars reticulata (SNr)/globus pallidus
interna (GPi), which is the initial portion of the direct excitability
pathway; D1 receptors are expressed on the surface of this
type of GABA-ergic neuron. The other type of GABA-ergic
neuron projects to the globus pallidus externa (GPe). The
inhibitory GABA-ergic neurons project from the GPe to the
FIGURE 3 | A hypothetical model of polysynaptic effects causing
ATS use disorders. The degrees of enhancement and reduction are
represented by the thickness of the lines. D2, dopamine D2 receptor;
D1, dopamine D1 receptor; GPe, external globus pallidus; GPi, internal
globus pallidus; STN, subthalamic nucleus; SNc, substantianigra pars
compacta; SNr, substantianigra pars reticulate. Top panel: Normal state:
Organization of intrinsic connections within the basal ganglia. The basal
ganglia output is determined by the balance between the direct
pathway and the indirect pathway. Bottom panel: ATS increase the
glutamate and dopamine level in the striatum, and ATS disturb the
inhibitory effect which the GABA interneurons exert on the GABA
projection neurons. Under the action of dopamine, the D1 and D2
receptors cooperate to activate the direct pathway and to inhibit the
indirect pathway. Through the activated direct pathway, the derepression
release of glutamate projected from the thalamus to cortex ultimately
increase glutamate release from the cortex to the striatum.
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subthalamic nucleus (STN). The glutamatergic neurons project
from the STN to the SNr/GPi, which is referred to as the
indirect pathway; these neurons are characterized by the surface
expression of D2 receptors. The direct and indirect pathways
converge in the SNr/GPi, the GABA-ergic neurons project
from the SNr to the thalamus, and the glutamatergic neurons
project from the thalamus to the cortex. Activation of the direct
pathway excites the brain cortex, whereas excitement of the
indirect pathway inhibits the activation of the cortex (Altar
and Hauser, 1987; Haber and Knutson, 2010). The striatum
receives projections from the dopaminergic neurons in the
meso-substantia nigra pars compacta (Balleine et al., 2007;
Nicola, 2007), and projections from the PFC glutamatergic
neurons (Alexander and Crutcher, 1990; Haber and Knutson,
2010). These regions and pathways form the nigrostriatal and
corticostriatal circuits, which may play an important role in ATS
abuse.
Interneurons within the striatum inhibit the GABA-ergic
projection neurons (Rymar et al., 2004), and the neurons that
express parvalbumin (PV) are the GABA-ergic interneurons.
Parvalbumin-positive interneurons are the main type of
interneurons that are identified as the junctions between afferent
and efferent nerves (Kawaguchi et al., 1995; Plotkin et al.,
2005). Compared with the GABA-ergic projection neurons,
the GABA-ergic interneurons receive information from the
cortex more easily and readily. After a quick response, all of the
types of GABA-ergic projection neurons cause fast and strong
inhibitory effects (Do et al., 2012). One study reported that the
stimulation projected from the cortex activated GABA-ergic
interneurons in the striatum, which inhibited the functions of
the GABA-ergic efferent nerves, whereas the GABAA receptor
antagonist picrotoxin blocked this inhibitory effect between
the interneurons and efferent nerves (Mallet et al., 2005). From
these studies, we conclude that the GABA-ergic interneurons
in the striatum adjust the function of the nigrostriatal and
corticostriatal circuits.
Influence of ATS Use Disorders on GABA System in
the Striatum-Related Neural Circuit (see Figure 3:
Bottom Panel)
Acute administration of ATS enhances the striatal projections
from the mesolimbic dopamine system (Ujike, 2002; Woodward
et al., 2011) and the PFC glutamate system (Stephans and
Yamamoto, 1994). The activated striatal neurons respond
to the information transported from the PFC and produce
changes in synaptic plasticity. Increased dopamine release
in the striatum activates the GABA-ergic projection neurons
that express D1 receptors and activates the direct pathway.
The D2 receptor-expressing GABA-ergic projection neurons
are suppressed (Surmeier et al., 2007), inhibiting the indirect
pathway. Under the action of dopamine, the D1 and D2
receptors cooperate to activate the direct pathway and to inhibit
the indirect pathway. Through the direct pathway, GABA-
ergic neurons projected from the striatum to the SNr/GPi are
activated, and GABA-ergic neurons projection from the SNr/GPi
to the thalamus are inhibited (Altar and Hauser, 1987; Mark
et al., 2004), leading to the derepression of the release of
glutamate from thalamus to cortex (Mark et al., 2004) and
ultimately promoting increased release of the cortical glutamate
(Timmerman and Westerink, 1997). The high cortical glutamate
level results in increased projection to the striatum through the
corticostriatal pathway, which promotes positive-feedback action
(Stephans and Yamamoto, 1994; Bellomo et al., 1998).
ATS inhibit the functions of the striatal GABA-ergic
interneurons (Centonze et al., 2002) and decrease the
benzodiazepine receptor binding sites of the striatal
GABAA receptors (Yoo et al., 2010). Large-dose injections
of methamphetamine (40mg/kg) over seven continuous days
could activate the apoptotic cascade of mouse striatal GABA-
ergic neurons (Jayanthi et al., 2004). Zhu et al. (2006) reported
that a large dose of methamphetamine (30–40mg/kg) induced
45% apoptosis of the parvalbumin-positive neurons in the
striatum. However, the somatostatin-positive neurons could
tolerate ATS-induced apoptosis. These results demonstrated that
because of the massive release of glutamate and dopamine in
the striatum, GABA interneurons in the striatum are susceptible
to ATS-induced apoptosis and the accompanying cytotoxic
effects (Nash and Yamamoto, 1992). Apoptosis of GABA-ergic
interneurons in the striatum leads to decreased inhibition of
GABA-ergic projection neurons and increases the release of
GABA in the SNr, which would inhibit tonic GABA in the
thalamus, allowing glutamate signals to fire in the cortex and
further activate cortical neurons. Finally, the effect of ATS would
enhance the positive-feed back action.
This evidence shows that ATS enhances the projections from
the cortex to the striatum and promotes dopamine projections
in the substantia nigra-striatum pathway, blocking the inhibitory
effects of the GABA-ergic interneurons and enhancing the
glutamate projections from the cortex to the striatum, thus finally
improving the glutamate functions in the striatum. Through
this positive feedback effect, long-time glutamate transmission
promotes changes in the neural synaptic plasticity and ultimately
results in the stabilization of addictive behavior (Yin and
Knowlton, 2006; Balleine et al., 2007).
Therefore, we can conclude that the activation of the
inhibitory effects of GABA-ergic interneurons in the striatum
may produce a series of biochemical and behavioral changes.
Researchers (Zhou et al., 2004) showed that systemic
administration of the GABAB receptor agonist, baclofen, reduced
the release of striatal dopamine and improved ATS-induced
hyper-activity. Few studies have reported the mechanisms of
involvement of the GABA system in ATS abuse. Exploration
in this field would offer new insight into the mechanisms
involved in ATS abuse and facilitate the development of new
medications for the treatment of ATS addiction andATS-induced
psychosis.
The biochemical function of the GABA system in ATS abuse
is through an inhibitory mechanism. The GABA systems in
the VTA, PFC, and striatum are connected by the mesolimbic,
mesocortic, and corticostriatal pathways, and they participate in
the development of ATS use disorders including ATS-induced
psychosis, as well as injury to cognitive functioning. This
finding provides a new insight into the treatment of ATS use
disorders.
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Genetic Studies on GABA System and ATS
Use Disorders
GABA System Genes are Associated with ATS
Use Disorders
In recent years, numerous research on twins or adoptees
suggested that genetics play a key role in drug use disorders
(Vanyukov and Tarter, 2000). The effect of genetic factors is
found in 33–79% of ATS abuse cases (Bousman et al., 2009).
At present, the associative genes involved in ATS addiction are
predominantly monoamine neurotransmitter genes, particularly
those that regulate dopamine functions and neuropeptides
and their receptors (e.g., prodynorphin and opioid receptors).
Additionally, there are reports on the GABA system genes that
are associated with ATS use disorders. A case-control study
(Nishiyama et al., 2005) showed that the GABAAγ2 subunit is
associated with ATS addictive behaviors. Another study (Lin
et al., 2003) analyzed the GABAA subunit genes located on
chromosome 5q33 in ATS addicts and found that the human
GABAAα1 (rs2279020) and γ2 (rs4480617) genes were associated
with ATS addiction. The GABAAγ2 gene was reported to be
involved in schizophrenia as well (Zai et al., 2009). These results
indicate that the GABA system genes may be associated with
ATS use disorders. Addictive drug abuse is hypothesized to be
a polygenic inherited disease, and the GABA system genes may
work with genes in other systems to participate in drug use
disorders.
Genetic experiments on rodents showed that ATS could
affect the function of the GABA system. Using two mouse
lines selectively bred for high methamphetamine-induced
activity (HMACT) or low methamphetamine-induced activity
(LMACT), Palmer et al. (2005) found an increase in the
GABAB1 gene expression level in the NAc tissues in the HMACT
group. This finding may reflect a compensatory response to
excessive activity of the VTA-NAc circuit in the HMACT
line or heightened expression of GABAB1 because of a low
resting tone of the ventral tegmental area of the GABA-ergic
system.
Epigenetic Changes may be Involved in ATS Use
Disorders
Accumulating data show that epigenetic changes such as miRNA
changes are involved in drug addiction (Sartor et al., 2012). Most
research focuses on traditional addictive drugs such as cocaine,
nicotine, alcohol, or opioids, and few studies have focused
on ATS addiction. Animal studies manifested an enhanced
miRNA181 level following ATS treatment (Saba et al., 2012),
and such up-regulation was hypothesized to be closely associated
with the development of schizophrenia (Beveridge et al., 2008).
One of the target genes of miRNA181 is the GABAAα1
subunit (Zhao et al., 2012), which suggests a relationship
between the GABAA receptor and ATS use disorders that is
in accordance with the above findings. Therefore, miRNA181
may be involved in ATS use disorders through regulation of the
GABA genes. Validated data are lacking, and further studies are
needed.
Experimental Genetic Techniques Studies
Experimental genetic techniques are an important source of
new knowledge about the interrelationship of genetic factors
and behavioral outcomes in substance abuse. Studies using
the molecular genetic technique, including gene silencing or
knock-out methods confirmed the involvement of the GABA
system in ATS use disorders. Adopting bacterial, artificial
chromosome-driven and miRNA silencing technology, the
Schmidt research group (Schmidt et al., 2014) generated a
transgenic mouse line, in which glutamic acid decarboxylase 1
(GAD1) expression was suppressed in cholecystokinin (CCK)
or neuropeptide Y (NPY)-expressing GABA-ergic interneurons.
They measured the locomotor responses of these transgenic
mice following a single dose of amphetamine at 3mg/kg.
Their results showed that the NPYGAD1TG mice (mice with
GAD1-suppressing bacterial, artificial chromosome constructs in
NPY+ interneurons) displayed a significantly greater increase
of up to a 600% peak response to amphetamine compared
with the littermate controls. In a separate experiment, the
CCKGAD1TG mice (mice with GAD1-suppressing bacterial,
artificial chromosome constructs in CCK+ interneurons)
showed a approximately 50% reduction in the peak response.
A possible explanation was that CCK+ and NPY+ GABA-ergic
interneurons were distributed to different areas in the brain,
which induced complex functional changes in the brain neural
circuits and consequently led to different behavioral responses
(Chronwall et al., 1985; Meziane et al., 1997). Elucidation of the
exact mechanisms requires further studies.
Researchers (Reynolds et al., 2003) pretreated GABAAα1
knock-out mice with amphetamines and found that their
stereotypical responses were enhanced whereas no changes
were seen in the hyper-locomotor responses. Because the
hyper-locomotorresponse is mainly correlated with nucleus
accumbens (Pijnenburg and van Rossum, 1973; Kelly and
Iversen, 1976) and the stereotypical response is related to
the dorsal striatum (Joyce and Iversen, 1984; Staton and
Solomon, 1984), the changes in the stereotypical responses in
amphetamine-treated GABAAα1knock-out mice indicate that
the dorsal striatal GABAAα1 subunit may play a more important
role in ATS abuse.
GABA System Targeted Medicine and Its
Clinical Applications in ATS Use Disorders
(see Figure 4)
This evidence demonstrates that the GABA system is involved
in ATS use disorders, and interventions focused on the GABA
system may provide a possible novel treatment for ATS use
disorders. Some studies have attempted to use GABA system
medicines to treat ATS use disorders. Benzodiazepines, which
are GABAA receptor agonists, are frequently used in the
clinic to treat psychiatric symptoms caused by ATS-induced
central nervous system hyper-activation (Merckmanuals1). Pre-
administration of benzodiazepines, such as alprazolam (0.5mg),
1http://www.merckmanuals.com/professional/special_subjects/drug_use_and_
dependence/amphetamines.html
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FIGURE 4 | The pharmacological and genetical therapeutical
strategies for ATS use disorders. The X marks represent the decreased
function. GABA, gamma-aminobutyric acid; GAD, glutamic acid
decarboxylase; GAT, GABA transporters; GABAA, GABAA receptor; GABAB,
GABAB receptor. (1) Alprazolam and Topiramate: They enhance
GABAA-mediated an influx of chloride ions further to promote rapid inhibitory
neurotransmission. (2) Baclofen: Baclofen enhances GABAB-mediated an
influx of potassium thus induces a slow inhibitory postsynaptic current. (3)
Gabapentin: GABA analog. (4) Vigabatrin: As a GAT inhibitor, Vigabatrin
decreases reuptake of GABA and increases GABA level in the extracellular
space. (5) Gene Therapy and MiRNA may be ideal therapeutic choice for ATS
use disorders in the future. For example, MiRNA181 may modify GABAAα1
gene expression at posttranscriptional level and gene therapy may modify
GABAAα1, GABAAγ2 gene mutation.
could attenuated the discriminative stimulus effects of D-
amphetamine, and some of the self-reported drug effects (Rush
et al., 2004). The use of another GABAA receptor agonist,
topiramate (100–200 mg/d), could protect ATS-induced memory
impairment and reduce drug cravings (Johnson et al., 2007).
The administration of the GABAB receptor agonist, baclofen
(20mg/d), was reported to reduce the ATS dosage (Heinzerling
et al., 2006). Additionally, the GAT inhibitor, vigabatrin (1–
3 g/d), could reduce the dosage of ATS and has been shown
to be safe in humans (Brodie et al., 2005). Although the above
data demonstrate that medicines targeting the GABA system
are potential treatments for ATS use disorders, there are some
limitations.
First, some medications targeting the GABA system (e.g.,
benzodiazepines) are addictive themselves, which limits their
clinical applications. Second, the curative effects of the currently
used GABA system medicines could only partially inhibit the
ATS effect, and their efficacy is minimally satisfactory. Therefore,
more effective medicines are needed for ATS use disorders.
Third, only a small amount of GABA system medicines are
used in the treatment of ATS addiction in the clinic, and the
available effective clinical data are not sufficient to establish
safe guidelines for clinical applications. Fourth, gene mutation
and miRNAs are involved in addiction-related behaviors. That
therapies that target specific genes or miRNAs may be novel
effective interventions for the treatment of ATS use disorders.
Conclusion
The majority of previous studies on ATS use disorders focused
on the meso-corticolimbic dopamine system. The role of the
GABA system in ATS use disorders has received increasing
attention in recent years. This review focused on the role of
the GABA system and discussed the role of the GABA system
in the three classic pathways, as well as genetic research and
clinical applications for ATS use disorders. This review may
provids a better understanding ofmechanisms of the GABA-ergic
system in ATS use disorders. We find that ATS can have effect
on multiple members of the GABA-ergic system and eventually
lead to a decrease in GABA-ergic system function. The complex
relationships between GABA, dopamine and glutamic acid in
ATS use disorder, as well as the resulting pathological and
physiological changes, are manifested through the interaction
between neural circuits. We conclude that the GABA-ergic
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system are importantly involved in the development of ATS
use disorders through multiple pathways, and that therapies
or medicines that target specific members of the GABA-ergic
system may represent new avenues for the treatment of ATS use
disorders.
Further studies are needed for a better understanding of the
mechanism of the GABA system in ATS use disorders and the
search for a better treatment.
A considerable part of the explanation for ATS use
disorders attribute to the genetic effects. Researches on GABA
system-related genetic studies are not as much as the other
systems such as dopamine nowadays, which the future researches
should focus on. Epigenetics researches such as miRNAs and
their relationship with ATS use disorders are just started and less
well-studied, but still there are evidence certifying that ATS abuse
changes certain miRNAs expression. Future studies may reveal
more complex and intriguing properties of miRNAs in ATS
addiction. The molecular genetic technique of gene targeting to
create mice with specific gene knockout mutations in the central
nervous system should be further employed to gain insight into
the molecular and cellular basis of ATS addiction. This helps
to clarify the interaction between ATS use disorders and GABA
system.
Although GABA system medicines are already applied
clinically to treat ATS addiction associated symptoms, because
of the sedative effect or addictive characteristic by themselves,
their therapeutic effects are heavily discounted. Genetic studies
demonstrate that the influence of ATS on GABA system may
be more specific to GABA receptor subunits. For example,
human genetic researches showed the GABAAα1, GABAAγ2
subunits were associated with ATS addictive behaviors, and
animal genetic researches discovered the correlative relationship
between GABAAα1, GABAB1 and ATS addiction. Therefore,
discovering more targeted and effective medicines aiming at
GABA receptor subunits maybe a new developmental direction
in the future. In addition, in the practical treatments on opioids
withdrawal, researchers found that drug combination was more
effective, and would significantly reduced drug desire. Thus,
we hope a similar drug combination strategy could be applied
clinically and finally play a part in ATS use disorders.
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